662 related articles for article (PubMed ID: 20307208)
1. Control of immunity by the TNFR-related molecule OX40 (CD134).
Croft M
Annu Rev Immunol; 2010; 28():57-78. PubMed ID: 20307208
[TBL] [Abstract][Full Text] [Related]
2. OX40, OX40L and Autoimmunity: a Comprehensive Review.
Webb GJ; Hirschfield GM; Lane PJ
Clin Rev Allergy Immunol; 2016 Jun; 50(3):312-32. PubMed ID: 26215166
[TBL] [Abstract][Full Text] [Related]
3. OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses.
Goulding J; Tahiliani V; Salek-Ardakani S
Immunol Rev; 2011 Nov; 244(1):149-68. PubMed ID: 22017437
[TBL] [Abstract][Full Text] [Related]
4. OX40 and OX40L Interaction in Cancer.
Lu X
Curr Med Chem; 2021; 28(28):5659-5673. PubMed ID: 33372866
[TBL] [Abstract][Full Text] [Related]
5. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.
Redmond WL; Weinberg AD
Crit Rev Immunol; 2007; 27(5):415-36. PubMed ID: 18197805
[TBL] [Abstract][Full Text] [Related]
6. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.
Ishii N; Takahashi T; Soroosh P; Sugamura K
Adv Immunol; 2010; 105():63-98. PubMed ID: 20510730
[TBL] [Abstract][Full Text] [Related]
7. OX40L/OX40 axis impairs follicular and natural Treg function in human SLE.
Jacquemin C; Augusto JF; Scherlinger M; Gensous N; Forcade E; Douchet I; Levionnois E; Richez C; Lazaro E; Duffau P; Truchetet ME; Seneschal J; Couzi L; Pellegrin JL; Viallard JF; Schaeverbeke T; Pascual V; Contin-Bordes C; Blanco P
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568041
[TBL] [Abstract][Full Text] [Related]
8. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
9. The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.
Nuebling T; Schumacher CE; Hofmann M; Hagelstein I; Schmiedel BJ; Maurer S; Federmann B; Rothfelder K; Roerden M; Dörfel D; Schneider P; Jung G; Salih HR
Cancer Immunol Res; 2018 Feb; 6(2):209-221. PubMed ID: 29321210
[TBL] [Abstract][Full Text] [Related]
10. OX40/OX40L axis: not a friend in autoimmunity.
Ueno H; Blanco P
Oncotarget; 2015 Sep; 6(26):21779-80. PubMed ID: 26314852
[No Abstract] [Full Text] [Related]
11. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
Kondo K; Okuma K; Tanaka R; Zhang LF; Kodama A; Takahashi Y; Yamamoto N; Ansari AA; Tanaka Y
Hum Immunol; 2007 Jul; 68(7):563-71. PubMed ID: 17584577
[TBL] [Abstract][Full Text] [Related]
12. Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity.
Rothfelder K; Hagelstein I; Roerden M; Blumenstock G; Hofmann M; Nuebling T; Jung G; Salih HR; Dörfel D
Neoplasia; 2018 Nov; 20(11):1150-1160. PubMed ID: 30300827
[TBL] [Abstract][Full Text] [Related]
13. OX40 (CD134) and OX40L.
Gough MJ; Weinberg AD
Adv Exp Med Biol; 2009; 647():94-107. PubMed ID: 19760068
[TBL] [Abstract][Full Text] [Related]
14. The significance of OX40 and OX40L to T-cell biology and immune disease.
Croft M; So T; Duan W; Soroosh P
Immunol Rev; 2009 May; 229(1):173-91. PubMed ID: 19426222
[TBL] [Abstract][Full Text] [Related]
15. OX40 signaling directly triggers the antitumor effects of NKT cells.
Zhou D
J Clin Invest; 2007 Nov; 117(11):3169-72. PubMed ID: 17975660
[TBL] [Abstract][Full Text] [Related]
16. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21.
Kweon S; Phan MT; Chun S; Yu H; Kim J; Kim S; Lee J; Ali AK; Lee SH; Kim SK; Doh J; Cho D
Front Immunol; 2019; 10():879. PubMed ID: 31105701
[No Abstract] [Full Text] [Related]
17. OX40: Structure and function - What questions remain?
Willoughby J; Griffiths J; Tews I; Cragg MS
Mol Immunol; 2017 Mar; 83():13-22. PubMed ID: 28092803
[TBL] [Abstract][Full Text] [Related]
18. OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling.
So T; Choi H; Croft M
J Immunol; 2011 Mar; 186(6):3547-55. PubMed ID: 21289304
[TBL] [Abstract][Full Text] [Related]
19. Serial OX40 engagement on CD4+ T cells and natural killer T cells causes allergic airway inflammation.
Damayanti T; Kikuchi T; Zaini J; Daito H; Kanehira M; Kohu K; Ishii N; Satake M; Sugamura K; Nukiwa T
Am J Respir Crit Care Med; 2010 Apr; 181(7):688-98. PubMed ID: 20019337
[TBL] [Abstract][Full Text] [Related]
20. Signaling through OX40 enhances antitumor immunity.
Jensen SM; Maston LD; Gough MJ; Ruby CE; Redmond WL; Crittenden M; Li Y; Puri S; Poehlein CH; Morris N; Kovacsovics-Bankowski M; Moudgil T; Twitty C; Walker EB; Hu HM; Urba WJ; Weinberg AD; Curti B; Fox BA
Semin Oncol; 2010 Oct; 37(5):524-32. PubMed ID: 21074068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
